Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Technology License Triggers $10 Million Milestone Payment for Biopharma
News Update

Share on Stocktwits


This is the first of many such potential payments under the related agreement.

DURECT Corp. (DRRX:NASDAQ) announced in a news release that it earned a $10 million milestone payment from Gilead Sciences Inc. (GILD:NASDAQ) for Gilead having advanced a long-acting injectable HIV investigational product using DURECT's SABER technology.

SABER, or sucrose acetate isobutyrate extended release, is a patented technology which provides sustained release for long-acting injectable products.

"Our license agreement with Gilead is part of DURECT's broader strategy to enter into selective collaborations and other arrangements for our technologies and product development programs," DURECT President and CEO James E. Brown said in the release. "By leveraging our resources with corporate collaborators, we believe we can retain commercial interest in multiple product candidates and maximize value for our shareholders."

Remaining milestones under this DURECT-Gilead agreement include the potential for up to another $65 million in development and regulatory milestones plus up to $70 million in sales-based milestones along with tiered royalties on product sales.

According to the release, "Gilead also received exclusive access to the SABER platform for HIV and hepatitis B virus (HBV) and the exclusive option to license additional SABER-based products directed to HIV and HBV for an additional $150 million per product in upfront, development, regulatory and sales based milestones as well as tiered royalties on sales. The parties will collaborate on specified development activities with Gilead controlling and funding the development programs."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT Corp.. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe